Recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)

US8029800B2 · kind B2 · utility

Assignee

• Bavarian Nordic A/S · DK

Inventors

• Paul Howley · Scone, AU
• Sonja Leyrer · Munich, DE
• Paul Chaplin · Munich, DE
• Eva Felder · Munich, DE

Key dates

• Filing date: Feb 26, 2009
• Grant date: Oct 4, 2011
• Expiry date: Aug 30, 2029

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.